Paper36923358
Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
Qi X and 2 others. Front Pharmacol, 2023. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective. Papers, record 36923358. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923358
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33314568 | Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. | J Cell Mol Med | 2021 | https://conductscience.org/library/papers/33314568 | PubMed |
| 2 | 9434895 | Structures of Src-family tyrosine kinases. | Curr Opin Struct Biol | 1997 | https://conductscience.org/library/papers/9434895 | PubMed |
| 3 | 28314257 | Treatment of Hematological Malignancies with Glycyrrhizic Acid. | Anticancer Res | 2017 | https://conductscience.org/library/papers/28314257 | PubMed |
| 4 | 34299273 | Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34299273 | PubMed |
| 5 | 29954750 | Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. | Blood | 2018 | https://conductscience.org/library/papers/29954750 | PubMed |
| 6 | 32419317 | TNF-α/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury. | Cell Prolif | 2020 | https://conductscience.org/library/papers/32419317 | PubMed |
| 7 | 30459751 | Glycyrrhizin Attenuates Salmonella enterica Serovar Typhimurium Infection: New Insights Into Its Protective Mechanism. | Front Immunol | 2018 | https://conductscience.org/library/papers/30459751 | PubMed |
| 8 | 35101664 | Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. | Biochem Biophys Res Commun | 2022 | https://conductscience.org/library/papers/35101664 | PubMed |
| 9 | 33505216 | Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids. | Mediators Inflamm | 2021 | https://conductscience.org/library/papers/33505216 | PubMed |
| 10 | 20453436 | Glycyrrhizin attenuates mucus production by inhibition of MUC5AC mRNA expression in vivo and in vitro. | J Pharmacol Sci | 2010 | https://conductscience.org/library/papers/20453436 | PubMed |
| 11 | 30884430 | Glycyrrhizin administration ameliorates Streptococcus aureus-induced acute lung injury. | Int Immunopharmacol | 2019 | https://conductscience.org/library/papers/30884430 | PubMed |
| 12 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 13 | 25660970 | Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. | Mol Immunol | 2015 | https://conductscience.org/library/papers/25660970 | PubMed |
| 14 | 33773396 | Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. | Cytokine | 2021 | https://conductscience.org/library/papers/33773396 | PubMed |
| 15 | 31270272 | The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/31270272 | PubMed |
| 16 | 30634142 | Glycyrrhizin attenuates hepatic ischemia-reperfusion injury by suppressing HMGB1-dependent GSDMD-mediated kupffer cells pyroptosis. | Int Immunopharmacol | 2019 | https://conductscience.org/library/papers/30634142 | PubMed |
| 17 | 30013568 | Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release. | Front Immunol | 2018 | https://conductscience.org/library/papers/30013568 | PubMed |
| 18 | 23983372 | Antiviral and immune stimulant activities of glycyrrhizin against duck hepatitis virus. | Afr J Tradit Complement Altern Med | 2012 | https://conductscience.org/library/papers/23983372 | PubMed |
| 19 | 32562521 | Preclinical Evidence for the Pharmacological Actions of Glycyrrhizic Acid: A Comprehensive Review. | Curr Drug Metab | 2020 | https://conductscience.org/library/papers/32562521 | PubMed |
| 20 | 33750071 | Cytokine Release Syndrome Biology and Management. | Cancer J | 2021 | https://conductscience.org/library/papers/33750071 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41105346 | Targeting the NLRP3 inflammasome with natural products for ischemia-reperfusion injury across organs: mechanisms, structure-activity relationships, and delivery innovations. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/41105346 | PubMed |
| 39091493 | CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. | Front Immunol | 2024 | https://conductscience.org/library/papers/39091493 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36923358
GET https://conductscience.org/api/papers/v1/36923358/references?page=2